Growth StrategyThe appointment of Luigi Ferrari as a board member and senior advisor is expected to support Valtecne's growth through enhanced commercial strategy and international development.
Market PerformanceThe Medical Devices division showed strong organic growth, driven by a buoyant orthopaedics market and increased product outflow related to VMI agreements.
Valuation And Price TargetThe company updated its valuation criteria, leading to a new DCF-based price target of €8.90 per share, representing a 26.2% upside potential to current price levels.